



Role of AI in Drug Discovery

Deependra Singh

Pt. Ravishankar Shukla University, Raipur Chhattisgarh, India.

deependraiop@gmail.com

EDITORIAL

Open Access

ARTICLE INFORMATION

Received: December 05, 2025
Published Online: January 09, 2026

Keywords:

Artificial intelligence, Drug discovery, Machine learning, Deep learning, ADMET, Clinical trials, Target identification, Neural networks

ABSTRACT

Background: The pharmaceutical industry is undergoing rapid digital transformation, generating vast and complex datasets that challenge traditional drug discovery workflows. Artificial intelligence (AI) has emerged as a powerful solution capable of processing large-scale clinical, biological, and chemical information with high precision. Its ability to learn from data, uncover hidden patterns, and automate complex tasks positions AI as a transformative force in modern drug development.

Objective: This editorial, through an AI lens in drug discovery, demonstrates the significance of AI applications in target identification, hit generation, lead optimization, predictive toxicology, ADMET profiling, and clinical trial design, and the issues and ethical considerations. The difficulties were acknowledged.

Results: AI showed massive power in foreseeing drug–target interactions, virtually testing millions of compounds, and creating new chemical structures with better pharmacological profiles. Deep learning techniques were far superior to conventional machine learning methods when predicting ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties. The use of AI to perform virtual screening and generate modeling rapidly led to the identification of new drug candidates, while clinical trial design was improved through data-driven algorithms enabling enhanced patient stratification and adaptive protocol utilization. Moreover, AI techniques allowed for the earliest possible toxicity prediction, thus lowering last-stage failures and overall development costs.

Conclusion: AI is a significant paradigm shift in drug discovery, which means therapeutics will be developed in a shorter period, at a lower cost, and with higher accuracy. However, the maximum benefit of AI can be achieved only if the technical, ethical, and regulatory challenges are solved through collaborative, transparent, and safe usage of AI-driven innovation facilitation frameworks.



DOI: [10.15415/jptm.2025.131011](https://doi.org/10.15415/jptm.2025.131011)

1. Introduction

In recent years, the pharmaceutical industry has seen a significant surge in data digitalization. Despite its benefits, this transformation presents notable challenges in acquiring, analyzing, and effectively utilizing complex clinical information. Artificial intelligence (AI) has emerged as a valuable tool due to its ability to process large datasets with high levels of automation. AI comprises sophisticated systems and algorithms designed to emulate human cognitive functions. AI-driven technologies can interpret data inputs, learn from them, and make autonomous decisions aimed at achieving specific goals. The global pharmaceutical industry is undergoing a profound transformation driven by the urgent need to address complex health challenges while reducing the escalating costs and inefficiencies of

traditional drug development methods. Historically, the drug development process has been characterized by long timelines, enormous financial investments often exceeding billions of dollars, and high failure rates, particularly in the later stages of clinical trials. This model is becoming increasingly unsustainable in response to the increasing demand for personalized therapies and the expanding disease burdens, despite its scientific rigor.

The integration of AI into pharmaceutical research and development has emerged as a pivotal innovation. AI is not merely a technological upgrade; it represents a paradigm shift in the way biomedical research is conducted. Artificial intelligence is transforming drug development by enhancing the speed and accuracy of various stages, including predicting drug–target interactions, refining molecular structures, streamlining clinical trial designs, and

identifying new biomarkers. One of the main advantages of AI is its capacity to process and interpret vast and complex biological datasets, including genomic and proteomic data, electronic health records, and scientific literature. This capability allows researchers to uncover hidden patterns and potential therapeutic targets that conventional approaches often overlook. The convergence of data science and pharmacology is thus paving the way for more cost-effective, timely, and accurate treatment strategies.

Machine learning (ML) and deep learning (DL), in particular, have become foundational tools in modern drug discovery. In contrast to traditional trial-and-error techniques, AI-driven methods leverage vast datasets to generate predictive insights. These insights help find good drug targets, improve lead compounds, and predict bad effects or toxicities early in development. A landmark achievement in this space is AlphaFold by DeepMind, which has successfully predicted the three-dimensional structure of proteins from their amino acid sequences. This breakthrough addresses a longstanding challenge in structural biology and significantly advances the potential for structure-based drug design.

2. AI: Networks and Tools

AI comprises various methodological approaches such as reasoning, knowledge representation, and problem-solving. Within this broad spectrum, ML serves as a core component, empowering systems to detect and learn patterns from data through algorithm-driven analysis. A specialized subset of ML is DL, which employs artificial neural networks (ANNs), complex computational structures inspired by biological neural networks. These networks simulate the brain's function by transmitting signals between interconnected nodes known as perceptrons, which act similarly to neurons in the human brain. ANNs consist of layers of nodes that receive individual inputs and process them into outputs, either individually or collectively, depending on the applied algorithm. Different architectures of ANNs include multilayer perceptrons (MLPs), recurrent neural networks (RNNs), and convolutional neural networks (CNNs), all of which can be trained using supervised or unsupervised methods.

MLPs are primarily used for pattern recognition, optimization, system identification, and control tasks. They rely on forward-only supervised learning and are effective as universal pattern classifiers. RNNs, characterized by feedback loops, have memory capabilities that allow them to retain and utilize previous information; examples include Boltzmann machines and Hopfield networks. Conversely, CNNs are characterized by their localized connectivity and layered architecture, which makes them highly effective for

applications like image and video processing, biological data modeling, complex pattern detection, and signal analysis.

In addition to these core types, more sophisticated neural network models include Kohonen networks, radial basis function (RBF) networks, learning vector quantization (LVQ) networks, counter-propagation networks, and ADALINE networks. Numerous AI-driven tools have emerged based on these neural network frameworks. A prominent example is IBM Watson, a supercomputer developed by International Business Machines (IBM) in New York, USA. This system is designed to analyze and interpret medical data by correlating patient information with large datasets to recommend potential treatment strategies, particularly in oncology. Remarkably, Watson demonstrated its efficiency by identifying breast cancer in 60 seconds, showcasing the potential of AI in accelerating disease diagnosis and enhancing clinical decision-making.

3. AI in Drug Discovery

The extensive chemical space, consisting of over 10^{60} molecules, supports the creation of numerous drug molecules. However, the absence of advanced technologies constrains the drug development process, rendering it a lengthy and costly endeavor, which can be mitigated through the application of AI. Artificial intelligence is capable of identifying hit and lead compounds, facilitating a more efficient validation of drug targets and the optimization of drug structure design. While AI presents numerous benefits, it encounters notable data challenges, including the scale, growth, diversity, and uncertainty of the data. The data sets utilized for drug development within pharmaceutical companies can encompass millions of compounds, and conventional machine learning tools may struggle to effectively manage these types of data. A computational model based on quantitative structure-activity relationship (QSAR) can efficiently predict a substantial number of compounds or basic physicochemical parameters, including log P or log D. Nonetheless, these models remain distant from accurately predicting complex biological properties, including the efficacy and adverse effects of compounds. Furthermore, QSAR-based models encounter challenges including limited training sets, inaccuracies in experimental data within training sets, and insufficient experimental validations. Recently developed AI methodologies, including deep learning and pertinent modeling studies, can be utilized for the safety and efficacy evaluations of drug molecules through big data modeling and analysis. In 2012, Merck sponsored a QSAR ML challenge to evaluate the benefits of deep learning in the drug discovery process within the pharmaceutical sector. Deep learning models demonstrated considerable predictive capability

in comparison to conventional machine learning methods across 15 absorption, distribution, metabolism, excretion, and toxicity (ADMET) data sets of drug candidates.

4. Applications of AI in Drug Discovery Target Identification and Validation

Artificial intelligence algorithms conduct analyses on omics datasets to identify genes or proteins linked to disease phenotypes. Machine learning models that utilize network-based approaches are capable of identifying new targets and delivering insights into disease mechanisms, thereby offering a comprehensive understanding of pathophysiology. AI-driven high-throughput virtual screening can assess millions of compounds *in silico*, significantly minimizing the time and resources required for the initial identification of hits. Generative AI models have the capability to design innovative chemical entities with specific properties, thereby enhancing the quality of hits that progress to the lead optimization stage.

5. Predictive Toxicology and ADMET Profiling

Predictive toxicology and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling using AI play a pivotal role in modern drug discovery by enhancing the efficiency and accuracy of early-stage compound evaluation. AI-driven models can analyze large datasets to predict the pharmacokinetic and toxicological behavior of drug candidates, significantly reducing the reliance on costly and time-consuming *in vitro* and *in vivo* experiments. These tools help identify potential safety risks and undesirable properties early in the pipeline, allowing researchers to modify or eliminate unsuitable compounds before entering clinical trials. Additionally, AI algorithms can uncover hidden patterns in complex biological data, facilitating the design of safer and more effective drugs. By improving the prediction of ADMET properties, AI contributes to lowering drug attrition rates, accelerating development timelines, and reducing overall costs in pharmaceutical R&D.

6. Clinical Trial Design

AI plays a transformative role in clinical trial design during drug discovery by enhancing efficiency, accuracy, and decision-making. It helps identify suitable patient populations through predictive modeling and analysis of real-world data, ensuring better trial outcomes and reducing recruitment failures. AI algorithms can simulate virtual trials, forecast outcomes, and optimize trial protocols, thereby saving time and resources. Additionally, AI facilitates adaptive trial designs by continuously analyzing incoming data to modify parameters such as dosage or patient stratification in real-time. This dynamic approach improves the probability of success and accelerates the overall drug development process.

7. Challenges of AI in Drug Discovery

AI holds immense potential to revolutionize drug development; its integration into pharmaceutical research brings forth several significant challenges and ethical concerns. One of the primary issues lies in the quality, diversity, and potential bias of the data used to train AI systems. Inadequate or non-representative datasets can lead to skewed outputs, thereby compromising the reliability and safety of AI-generated predictions. Moreover, the “black box” nature of some AI algorithms restricts transparency and interpretability, making it challenging for researchers and regulatory authorities to comprehend how decisions such as drug candidate selection or toxicity prediction are derived. This opacity can undermine trust and delay the regulatory approval process. Ethical dilemmas also emerge, particularly around patient privacy, as AI often requires access to large volumes of sensitive health data, necessitating stringent data protection measures. Furthermore, the widespread use of AI could unintentionally deepen the divide between well-resourced and underserved regions, potentially exacerbating existing global health disparities. To address these issues, it is crucial for scientists, ethicists, policymakers, and regulatory authorities to work together to establish robust frameworks that promote fairness, ensure transparency, and prioritize human-centered values in the application of AI within drug discovery.